“If integration is being confirmed, copy number determination, integration site identification, and monitoring for any subsequent adverse biological effects and changes in cell behaviour should be performed.

Depending on the nature of the vector used, extended in vitro and in vivo assays addressing insertional oncogenesis may be warranted prior to first administration in humans.”

<Guideline on the quality, non-clinical and clinical aspectsof gene therapy medicinal products>